Russia experiences sharp growth in demand for diabetes drugs

Russia is experiencing a sharp growth in the demand for drugs against diabetes this year, particular those that are also used for weight loss, reports The Pharma Letter’s local correspondent.

In January of the current year sales of these drugs in most of Russian pharmacies increased by 50%-70% year-on-year basis, with the growth currently ongoing. At the same time, according to representatives of Russian pharmacies, the growth was even higher in value terms, exceeding 140%.

With expected drug sales for GLP-1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative market for drug developers.